Search Results - "Ryder, Mabel M"

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment by Shonka, David C., Ho, Alan, Chintakuntlawar, Ashish V., Geiger, Jessica L., Park, Jong C., Seetharamu, Nagashree, Jasim, Sina, Abdelhamid Ahmed, Amr H., Bible, Keith C., Brose, Marcia S., Cabanillas, Maria E., Dabekaussen, Kirsten, Davies, Louise, Dias‐Santagata, Dora, Fagin, James A., Faquin, William C., Ghossein, Ronald A., Gopal, Raj K., Miyauchi, Akira, Nikiforov, Yuri E., Ringel, Matthew D., Robinson, Bruce, Ryder, Mabel M., Sherman, Eric J., Sadow, Peter M., Shin, Jennifer J., Stack, Brendan C., Tuttle, R. Michael, Wirth, Lori J., Zafereo, Mark E., Randolph, Gregory W.

“…Background The development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a…”
Get full text

Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study by Abrahão, Renata, Brunson, Ann, Ruddy, Kathryn J., Li, Qian, Li, Judy, Ryder, Mabel M., Chubak, Jessica, Nichols, Hazel B., Sauder, Candice A. M., Gray, Marlaine F., Hahn, Erin E., Wun, Ted, Keegan, Theresa H. M.

“…Background Cancer survivors have increased risk of endocrine complications, but there is a lack of information on the occurrence of specific endocrinopathies…”
Get full text

Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy by Iñiguez-Ariza, Nicole M, Jasim, Sina, Ryder, Mabel M, Chintakuntlawar, Ashish V, Morris, John C, Hilger, Crystal R, Menefee, Michael E, Smallridge, Robert C, Karlin, Nina J, Alcaino, Constanza, Bible, Keith C

“…Abstract Context Clinical applications of genomic assessment of thyroid cancers are rapidly evolving. Objectives, Design, and Setting We studied tumor samples…”
Get full text

Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer by Iñiguez-Ariza, Nicole M, Ryder, Mabel M, Hilger, Crystal R, Bible, Keith C

“…Historical anaplastic thyroid cancer (ATC) outcomes have been terrible, with a median survival of only five months and <20% one-year survival. Improved…”
Get more information

OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS by Jasim, Sina, Iniguez-Ariza, Nicole M, Hilger, Crystal R, Chintakuntlawar, Ashish V, Ryder, Mabel M, Morris, 3rd, John C, Bible, Keith C

“…Lenvatinib is approved for use in advanced radioactive iodine-resistant differentiated thyroid cancers (RAIR-DTCs). Its efficacy is indisputable, but…”
Get more information

7911 High Dose Serial Radioactive Iodine Therapies Facilitated byAutologous Stem Cell Cryopreservation in a Patient with Exceptionally Avid Metastatic FTC by Paknikar, Sujaytha, Tobon, David Toro, Durski, Jolanta, Alkhateeb, Hassan, Ryder, Mabel M

“…Abstract Disclosure: S. Paknikar: None. D. Toro Tobon: None. J. Durski: None. H. Alkhateeb: None. M.M. Ryder: None. Introduction: Radioactive iodine (RAI)…”
Get full text

THU535 Anti-angiogenic Multi-kinase Inhibitor In NUTM1 Rearranged Carcinoma Of Thyroid by Tella, Sri Harsha, Morris, John C, Rivera, Michael, Gupta, Sounak, Ryder, Mabel M

“…Abstract Disclosure: S. Tella: None. J.C. Morris: None. M. Rivera: None. S. Gupta: None. M.M. Ryder: None. Introduction: NUT carcinoma is a rare subtype of…”
Get full text

7478 Effects of RAI on Papillary Thyroid Carcinoma with Positive Lymph Nodes by Rachmasari, Kharisa N, Osman, Alsayed, Tobon, David Toro, Lund, Sarah B, Merlino, Dante J, Hsu, Andrea R, Ryder, Mabel M

“…Abstract Disclosure: K.N. Rachmasari: None. A. Osman: None. D. Toro Tobon: None. S.B. Lund: None. D.J. Merlino: None. A.R. Hsu: None. M.M. Ryder: None…”
Get full text

SAT520 Efficacy of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers by Toro-Tobon, David, Morris, John C, Hilger, Crystal, Peskey, Candy S, Jolanta, Durski M, Ryder, Mabel M

“…Abstract Disclosure: D. Toro-Tobon: None. J.C. Morris: None. C. Hilger: None. C.S. Peskey: None. D.M. Jolanta: None. M.M. Ryder: None. Objective: Patients with…”
Get full text

Aggressive Thyroid Cancer is Associated With Suppressor Circulating Immunophenotype by Kotwal, Anupam, Bornschlegl, Svetlana, Gustafson, Michael, Dietz, Allan, Delivanis, Danae Anastasia, Ryder, Mabel M

“…Abstract Introduction: The influence of the immune system on follicular cell-derived thyroid cancer behavior has been suggested by various studies but this…”
Get full text

NTRK1-3 point mutations in poor prognosis thyroid cancers by Iniguez-Ariza, Nicole M., Bible, Keith Christopher, Morris, John C., Chintakuntlawar, Ashish V., Shridhar, Vijayalakshmi, Smallridge, Robert C., Menefee, Michael E., Hilger, Crystal, Severson, Eric Allan, Ryder, Mabel M

“…Abstract only 6087 Background: NTRK1-3 fusions, identified in pediatric radiation-associated thyroid cancers, are low frequency oncogenic drivers that can…”
Get full text

OR32-02 Immune Checkpoint Inhibitor-Induced Hypophysitis Is Associated with Improved Overall Survival in Cancer Patients by Kotwal, Anupam, Rouleau, Samuel G, Kottschade, Lisa, Ryder, Mabel M, Kudva, Yogish C, Markovic, Svetomir, Erickson, Dana Z

“…Abstract Context: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies against checkpoints namely CTLA-4, PD-1 and PD-L1. These can cause pituitary…”
Get full text